Publikasjoner
Konferanseabstrakt
- Mona Stedenfeldt; Pål Øian; Elisabeth Hals et al. (2013). A HIGHLY SUCCESSFUL INTERVENTIONAL PROGRAM REDUCING THE INCIDENCE OF OASIS FROM 4.7 TO 2.0 PERCENT IN A LARGE COHORT. (ekstern lenke)
- Ingvild Vistad; Mette Skorstad; Milada Hagen et al. (2025). The Impact Of The LETSGO Personalized Follow-Up Model On Empowerment And Quality Of Life In Gynaecological Cancer Survivors: A Multicenter Quasi-Experimental Study. (ekstern lenke)
Vitenskapelig artikkel
- Elisabeth Hals; Pål Øian; Tiina Tellervo Pirhonen et al. (2010). A Multicenter Interventional Program to Reduce the Incidence of Anal Sphincter Tears. (ekstern lenke)
- David Erik Forsse; Mark Lewis B Barbero Barbero; Henrica Maria Johanna Werner et al. (2021). Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study. (ekstern lenke)
- Cecilie Fredvik Torkildsen; Marie Austdal; Ann-Charlotte Iversen et al. (2023). Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins. (ekstern lenke)
- Bente Vilming; Jørgen Fallås Dahl; Anne Gry Bentzen et al. (2023). Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer. (ekstern lenke)
- Cecilie Fredvik Torkildsen; Marie Austdal; Anders Hagen Jarmund et al. (2024). New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients. (ekstern lenke)
- Ingvild Vistad; Mette Skorstad; Sveinung Berntsen et al. (2025). Empowerment and quality of life in gynecological cancer survivors: Outcomes from a multicenter quasi-experimental cohort study from Norway (the LETSGO trial). (ekstern lenke)